← Leaderboards
David Eric Arterburn
Kaiser Foundation Health Plan Of Washington
$8,738,288
Attributed
$14,474,600
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,474,600 · 7
By mechanism
R01$14,474,600 · 7
Top collaborators
- Matthew L Maciejewski6 shared
- Adam Drewnowski5 shared
- Karen Jacqueline Coleman4 shared
- Rozalina Grubina Mccoy2 shared
- Anne Evelyn Sales2 shared
Others in their field
Top investigators on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
ObesityCohortAdultFollow-UpNon-Insulin-Dependent Diabetes MellitusProspectiveMedicalHealth PlanningBariatric SurgeryHealth Care DeliveryBody Mass IndexWeightOperative Surgical ProceduresBaseComputerized Medical RecordHealthcare SystemsEconomicsBody WeightEventCharacteristicsComorbidityCaringGenderGlycemic Control
Grant awards (24)
Developing robust anti-Obesity Medication ImplemeNtatiOn approaches to maximize population health (the DOMINO study)$688,864
R01 · FY2025 · DK
Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes$660,172
R01 · FY2025 · DK · contact PI
Developing robust anti-Obesity Medication ImplemeNtatiOn approaches to maximize population health (the DOMINO study)$766,551
R01 · FY2024 · DK
Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes$696,763
R01 · FY2024 · DK · contact PI
Long-term Costs and Return on Investment for Bariatric Surgery$657,373
R01 · FY2023 · DK
Long-term Costs and Return on Investment for Bariatric Surgery$673,676
R01 · FY2022 · DK
Long-term Costs and Return on Investment for Bariatric Surgery$681,841
R01 · FY2021 · DK
Moving to Health: How changing built environments impact weight and glycemic control$494,562
R01 · FY2021 · DK · contact PI
Long-term Costs and Return on Investment for Bariatric Surgery$721,630
R01 · FY2020 · DK
Moving to Health: How changing built environments impact weight and glycemic control$525,866
R01 · FY2020 · DK · contact PI
Moving to Health: How changing built environments impact weight and glycemic control$497,730
R01 · FY2019 · DK · contact PI
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems$668,352
R01 · FY2018 · DK · contact PI
Moving to Health: How changing built environments impact weight and glycemic control$595,623
R01 · FY2018 · DK · contact PI
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems$644,094
R01 · FY2017 · DK · contact PI
Moving to Health: How changing built environments impact weight and glycemic control$582,395
R01 · FY2017 · DK · contact PI
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems$676,017
R01 · FY2016 · DK · contact PI
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems$755,977
R01 · FY2015 · DK · contact PI
Impact of Bariatric Surgery on Long-term Diabetes Remission and Complications$533,107
R01 · FY2015 · DK · contact PI
Impact of Bariatric Surgery on Long-term Diabetes Remission and Complications$560,222
R01 · FY2014 · DK · contact PI
Impact of Bariatric Surgery on Long-term Diabetes Remission and Complications$537,166
R01 · FY2013 · DK · contact PI
Impact of Bariatric Surgery on Long-term Diabetes Remission and Complications$660,619
R01 · FY2012 · DK · contact PI
Antidepressant Treatment and Risk of Obesity$396,000
R01 · FY2011 · MH · contact PI
Antidepressant Treatment and Risk of Obesity$400,000
R01 · FY2010 · MH · contact PI
Antidepressant Treatment and Risk of Obesity$400,000
R01 · FY2009 · MH · contact PI